Loading...
Market
What will be Cologuard Plus' revenue as a percentage of Exact Sciences' total revenue in 2025?
3
Resolution / Starting Odds
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Exact Sciences' 2025 financial report
Story
Exact Sciences' ($EXAS) Stock Rises as FDA Approves Cologuard Plus, Setting New Benchmark in Colorectal Cancer Screening
Oct 4, 2024, 04:49 PM
Exact Sciences (NASDAQ: EXAS) announced that on Friday it received approval from the U.S. Food and Drug Administration (FDA) for its Cologuard Plus™ test, an improved stool-based screening assay for colorectal cancer. The Cologuard Plus test is a next-generation multitarget stool DNA test designed for non-invasive colorectal cancer screening in adults aged 45 and older who are at average risk for colorectal cancer (CRC). The FDA approval sets a new benchmark in non-invasive colorectal cancer screening, providing an improved option for early detection of colon cancer. Following the announcement, Exact Sciences' stock price rose.
View original story
Similar markets
No similar markets found.